Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × tislelizumab × Breast × Clear all

Phase

Status

Unknown 5 Recruiting 4 Withdrawn 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Thoracic 2 Other solid neoplasm 2 Sarcoma 1 Other hematologic neoplasm 1 Head & Neck 1 Gynecologic 1 Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Paclitaxel 26 Trastuzumab 20 Cyclophosphamide 18 Docetaxel 15 Doxorubicin 13 Carboplatin 12 Radiotherapy 11 pembrolizumab 10 exemestane 10 Letrozole 10 Fulvestrant 10 Capecitabine 10 Lapatinib 8 eribulin 7 Magnetic Resonance Spectroscopy 7 Biopsy 7 Anastrozole 7 palbociclib 6 abemaciclib 6 Taxes 6 Goserelin 6 Aromatase Inhibitors 6 Therapeutics 5 Neoadjuvant Therapy 5 Mastectomy, Segmental 5 Drug Therapy 5 Cryosurgery 5 Chemotherapy, Adjuvant 5 Bevacizumab 5 Albumin-Bound Paclitaxel 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05809895 2023-07-24

AdvanTIG-211

Novartis

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡